ArticleMedizinische Klinik, Intensivmedizin und Notfallmedizin2026
Impella in infarction-related cardiogenic shock: evidence, complications, and implementation of microaxial LV unloading.
Article in Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) remains highly lethal despite early revascularization. Although left ventricular (LV) failure predominates, AMI-CS may also be triggered or dominated by right ventricular (RV) failure, which carries distinct implications for the choice of mechanical support. Escalating catecholamines may increase afterload, provoke arrhythmias, and raise myocardial oxygen demand. Microaxial left ventricular (LV) support (Impella) provides forward flow while unloading the LV, potentially improving the subendocardial perfusion gradient, reducing pulmonary congestion, and limiting catecholamine exposure. Net clinical benefit is conditional and must be balanced against a substantial and predictable complication burden (major bleeding, vascular/limb complications, hemolysis with acute kidney injury, and infection). In the DanGer Shock trial, a protocolized Impella CP strategy in selected patients with ST-elevation myocardial infarction (STEMI)-CS lowered 180-day mortality (45.8% vs. 58.5%; hazard ratio [HR]: 0.74) but increased major complications and renal replacement therapy. Conversely, early venoarterial extracorporeal membrane oxygenation (VA-ECMO [extracorporal membrane oxygenation]) in the ECLS (extra corporal life support)-SHOCK trial did not improve 30-day survival and increased bleeding and vascular complications. Clinically, Impella should be used as part of phenotype-driven shock pathways-early for LV-dominant, congested low-output shock with a reversible trajectory-combined with standardized access/anticoagulation bundles, close complication surveillance, and early reassessment with deliberate escalation or de-escalation.
Indexed as
Identifiers
42853380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.